BioCentury
ARTICLE | Company News

Thermogenesis hematology news

November 11, 2013 8:00 AM UTC

ThermoGenesis said it is eliminating 11 positions as part of a restructuring expected to save $1.5 million per year. The company said it will focus on speeding up adoption of its AXP AutoXpress Platform in developed and emerging markets. The platform has 510(k) clearance in the U.S. to isolate and capture stem cells from umbilical cord blood. AutoXpress also has CE Mark approval and marketing approval in China. General Electric Co. (NYSE:GE, Fairfield, Conn.) has exclusive, global distribution rights to the automated device and companion sterile closed blood processing disposable. ...